State of the Life Sciences Industry - Third Quarter Review

The global market for vision care is expected to grow from $75.1 billion in 2025 and is projected to reach $98 billion by the end of 2030, at a CAGR of 5.5% during the forecast period of 2025 to 2030.

The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable or slightly decline to $7.69 billion by the end of 2030, at a CAGR of -0.04% during the forecast period of 2025 to 2030.

The global market for anti-Parkinson’s drugs is projected to grow from $6.1 billion in 2025 to reach $9.2 billion by the end of 2030, at a CAGR of 8.6% from 2025 to 2030.

The life sciences sector is currently undergoing substantial change due to digital innovations, including artificial intelligence (AI), a rise in mergers and acquisitions and cross-industry partnerships, which are tackling issues such as data security, talent acquisition and adapting to changing regulatory environments. With great opportunities for deal-making and the commercialization of innovative therapeutics and diagnostic products, the industry remains a leader in creating revolutionary healthcare solutions, despite facing funding challenges and global concerns. By the end of 2025, digital transformation is likely to have an impact on organizational strategy. Over the next five years, biopharmaceutical companies are projected to make substantial investments in AI, which could lead to increased revenue across all areas. Compared to earlier digital advances, gen AI is believed to have greater transformative potential. By integrating gen AI into existing processes, it could reduce R&D costs, enhance customer self-service through digital channels, streamline back-office functions and increase individual productivity.

Companies in the life sciences industry are adapting to changing market dynamics through innovation. However, as innovation takes time, some biopharma companies are focusing on lucrative disease categories and indications, such as immunology and cancer, as these have evolved into profitable business categories. Many assets employ similar methods of action or target the same biological pathways. Even before generics or biosimilars hit the market, this overlap fosters competition, which can lower prices and have a detrimental effect on market share and profitability.

Report Scope

The report provides insights into cell biology, pharmaceuticals, biopharmaceuticals, medical devices, and surgical, as well as health maintenance verticals. The broad coverage of life sciences topics highlights the high-level summary to spark interest among the readers and provides insights related to market dynamics, emerging opportunities, regulatory frameworks, sustainability trends and analysis across diverse industries and trends from secondary sources in the form of a graph/chart/infographic (market size, growth rate, overall deployment, shipment, investment/funding) and their impact on market outlook. For an in-depth study across these verticals, the report offers various types of coverage to caters to a range of reader demands. The range of offerings includes syndicated market research reports, custom market research reports and data reports.